Alkermes
ALKS
$24.38
Share price
0.93%
Change (1 day)
-20.03%
Change (1 year)
Categories
Alkermes (ALKS) - P/B ratio
P/B ratio as of May 2024 : 3.40
According to Alkermes's latest financial reports the company has a price-to-book ratio of 3.40.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Alkermes - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 3.85 | -6.43% |
| 2022-12-31 | 4.11 | 21.68% |
| 2021-12-31 | 3.38 | 13.61% |
| 2020-12-31 | 2.98 | 0.35% |
| 2019-12-31 | 2.97 | -24.44% |
| 2018-12-31 | 3.92 | -43.92% |
| 2017-12-31 | 7.00 | 0.19% |
| 2016-12-31 | 6.98 | -23.27% |
| 2015-12-31 | 9.10 | 47.16% |
| 2014-12-31 | 6.19 | 12.27% |
| 2013-12-31 | 5.51 | 106.66% |
| 2012-12-31 | 2.67 | 7.23% |
| 2011-12-31 | 2.49 | -15.83% |
| 2010-12-31 | 2.95 | 39.37% |
| 2009-12-31 | 2.12 | -5.99% |
| 2008-12-31 | 2.25 | -44.57% |
| 2007-12-31 | 4.07 | -42.08% |
| 2006-12-31 | 7.02 | -91.14% |
| 2005-12-31 | 79.3 | 17.35% |
| 2004-12-31 | 67.6 | 455.15% |
| 2003-12-31 | 12.2 | 74.58% |
| 2002-12-31 | 6.97 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.32 | 56.42% | 🇺🇸 USA |
 Novartis NVS | 5.29 | 55.63% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.82 | -46.51% | 🇺🇸 USA |
 Sanofi SNY | 1.49 | -56.04% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 5.39 | 58.73% | 🇺🇸 USA |
 AstraZeneca AZN | 6.38 | 87.80% | 🇬🇧 UK |
 Acorda Therapeutics
ACOR | -0.0052 | -100.15% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 2.33 | -31.54% | 🇮🇱 Israel |